title: Dose-rate effects between 0.3 and 30 Gy/h in a normal and a malignant human cell line.
abstract: OBJECTIVE
  This study used continuous "intermediate" dose rate irradiation (0.3-30 Gy/h) to compare the capacity for and repair of sublethal radiation damage in different cell lines growing in tissue culture.
  
  
  METHODS
  Two human cell lines were studied; one was derived from normal human fibroblasts (AG1522) and the other from a squamous cell carcinoma of the uterine cervix (HTB-35). Dose-response curves for clonogenic survival were determined following irradiation of plateau-phase cultures at five different dose rates: 22.6, 6.12, 3.65, 1.04, and 0.38 Gy/h. Subculture following irradiation was delayed for 8-24 h to allow for the full repair of "potentially lethal damage."
  
  
  RESULTS
  A significant dose-rate effect was seen in both cell lines. For irradiation at the highest dose rate, survival at 2 Gy (SF2) and the alpha/beta ratio were similar for the two cell lines (approximately 0.7 and 8.0 Gy, respectively) but the half-time of repair of sublethal damage was estimated to be approximately five times longer in the normal human fibroblast line (154 min) than in the carcinoma (31 min) cell line.
  
  
  CONCLUSIONS
  These results indicate that measuring the dose-rate effect between 0.3 and 30 Gy/h is a useful way to identify and quantify differences in sublethal damage repair between cell lines. To the extent that in vitro and in vivo repair parameters are similar, and that representative tumor biopsy specimens can be examined in this way, this approach may provide a prospective way of determining the dose rate (brachytherapy) or fractionation schedule that will optimize the therapeutic ratio.
authors.affiliation: Department of Radiological Health Sciences, Colorado State University, Fort Collins 80523.
authors.forename: R J
authors.initials: RJ
authors.lastname: Amdur
authors.forename: J S
authors.initials: JS
authors.lastname: Bedford
mesh_terms: D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D002452:Cell Count / Q000528:radiation effects; D002453:Cell Cycle / Q000528:radiation effects; D002460:Cell Line; D002470:Cell Survival / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D005240:Feasibility Studies; D005260:Female; D005347:Fibroblasts / Q000528:radiation effects*; D006801:Humans; D011833:Radiation Injuries, Experimental / Q000209:etiology / Q000473:pathology; D011836:Radiation Tolerance; D014407:Tumor Cells, Cultured / Q000528:radiation effects; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy*